PolyTherics and BioVectra sign manufacturing and representation deal
PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, has signed a manufacturing and bilateral representation agreement with BioVectra, a Canadian firm that supplies specialty chemicals and contract manufacturing services to the pharmaceutical and biotechnology industry.
PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, has signed a manufacturing and bilateral representation agreement with BioVectra, a Canadian firm that supplies specialty chemicals and contract manufacturing services to the pharmaceutical and biotechnology industry.
The agreement will see BioVectra manufacturing high quality cGMP MPEG reagents to support clients" clinical development of PolyTherics" novel PEGylation technology. BioVectra will also market the PEGylation technology to its client base in North America.
The new PEGylation technology, known as TheraPEG, can extend the half-life of novel and existing protein drugs. This means that drugs, such as Interferon, stay active in the body for longer, enabling longer periods between doses. According to Polytherics, this means that patients can therefore be treated less often, with fewer side-effects and at lower cost.
The market for traditional PEGylation has expanded considerably and PolyTherics" TheraPEG technology is positioned both to address existing markets and open new markets, particularly in the antibody field, the company says.